Labiotech.eu’s Post

Let’s take a look at which companies raised the biggest private biotech investments in August 2024! 💸 Last month, Borealis Biosciences, Inc., Outpace Bio, and Halda Therapeutics bagged the biggest investments. 🚀 Borealis, which was launched in August by Novartis and Versant, brought in $150 million in a series A round. The new company will focus on developing next-generation xRNA-based medicines for kidney diseases. 🧬 But around the world, oncology players attracted the biggest funding rounds overall. 🧪 Read our latest article to find out more about last month’s biggest biotech rounds! 👇️ https://lnkd.in/dCqR_H7s #biotechinvestments #fundingrounds #xRNAinnovation #oncologybreakthroughs #biotechnews IDRx | Pathalys Pharma | Jade Biosciences | MBX Biosciences, Inc. | Red Queen Therapeutics | Healx | NOETIK | Seed Therapeutics | Tern Therapeutics | Diakonos Oncology | Talus Bio | Kinoxis Therapeutics Pty Ltd | Kano Therapeutics | Release Therapeutics | PhotonPharma

Huge start to 2024 in the fundraising arena. Some key financing milestones have been hit in the Biotech sector: 💹 Radionetics Oncology - $52.5 million Series A financing bringing their total investment to $82.5 million. A huge step for the Radiopharmaceutical company 💱 HI-Bio - $95 million in Series B financing to support their development of their in-licensed monoclonal antibody from Morphosys. 💰 Moonwalk Biosciences - $57 million to support their development of new epigenetic medicines 💲 Claris Bio - Broke stealth mode last Thursday with $57 million to develop drugs tackling Ocular diseases 💵 Lykos Therapeutics (formerly MAPS PBC) - A spin out from Multidisciplinary Association for Psychedelic Studies (MAPS) rebranding and bringing with it a huge fundraising round of $100 million to continue developing psychedelics 💶 VICO Therapeutics B.V. - $60 million Series B in order to support their Phase 1/2a clinical trial in Rare Neurological Diseases #fundraising #biotechinvestment #venturecapital

Latest Life Science News / Updates 👇 📌 TORL BioTherapeutics, LLC is the latest biotech to benefit from the ADC boom, bringing in $158 million in a B2 financing round. ➡ Asher Biotherapeutics has closed a $55 million series C to support the mission of developing therapies for cancer, autoimmune and infectious diseases. ◾ Canaan Partners adds $100m for Biotech investments plus brings in Uwe Schoenbeck to the team from Pfizer. 📌 Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its first-in-class solid tumor candidate in clinical trials by the end of the year. ◾ Alvotech and Teva Pharmaceuticals have announced approval from the FDA for Selarsdi via subcutaneous injection. ➡ Scopio Labs receives groundbreaking FDA Clearance for first-ever Digital Bone Marrow Aspirate application 📌 Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer ◾ Sensorium Therapeutics appoints Sam Rasty as Chief Business Officer

So, which companies managed to raise the biggest private biotech investments in September 2024? 📈 The top spot went to Candid Therapeutics, which launched with a $370 million series A round to develop T-cell engager antibodies. Meanwhile, Arsenal Biosciences, Inc. and eGenesis, Inc. raised the second and third largest rounds, respectively. 🚀 And, after a slow fundraising month in August, things appeared to be back to normal in September, as 11 more rounds took place than in August, with $937 million more raised. 💰 Read our latest article to find out more about last month’s fundraising trends! 👇️ https://lnkd.in/eWkKcJ8i #BiotechInvestments #BiotechFunding #FundraisingTrends #Biopharma #LifeSciences #SeriesARound #BiotechInnovation #InvestmentNews #StartupFunding #BiotechGrowth Aktis Oncology | Superluminal Medicines Inc. | Vicebio | F2G | Circle Pharma, Inc. | Nura Bio | OrsoBio| ONL Therapeutics | GC Therapeutics | Genespire | 858 Therapeutics | Radiant Biotherapeutics | Vironexis Biotherapeutics | Brenus Pharma | Feldan Therapeutics | Epsilogen Ltd

✨Introducing Champions' Transformative Drug Discovery Solutions✨ Our ChemiSelect and ADC-Flow integrated workflows are built to transform the scale and success of oncology discovery programs. ChemiSelect: rapidly screen and prioritize chemotypes for difficult-to-assay targets through high-throughput integrated workflows. Why Choose ChemiSelect:  🔬 Cell-Based Platform: reliably prioritize chemotypes in biologically relevant cellular context. 💰 Cost-Effective: Budget-friendly options with fast turnaround. 🛡️ Early Liabilities Mitigation: Effectively address ADMET concerns early. ADC-FLOW: Rapidly build and validate early translational strategies for effective ADC therapeutics. Why Choose ADC-FLOW: 🎯 Formulate Translational Hypotheses: Position your ADC program for success by unveiling your target patient population from the start. 🔍 Screen & Select: Efficiently and cost-effectively screen large antibody libraries, selecting mAb hits with internalization and cancer cell-killing capabilities. 🔬 Validate Hypotheses via ex-vivo Clinical Trial Simulations: Assess ADCs within clinically relevant cohorts. Learn more about Champions Oncology's Early Drug Discovery Solutions: https://hubs.li/Q02xk8Db0 #drugdiscovery #ADC #compoundscreening #drugscreening #tumorgraft3D #DRUGseq #3DPDXModels

Nice presentation of Champions workflows for Drug Discovery Solutions: - ChemiSelect - ADC Flow

Only a few days left to register for the 9th CAR-TCR Summit at the best rate! In case you haven't seen it yet, full agenda here: https://ter.li/eugziv This remains the industry's favorite meeting for CAR-T and TCR-based drug development, where you'll hear brand new insights from key academics, innovative biotechs and big-player pharma. We asked the industry what hot topics should be up for discussion this year - and you have spoken! So, in 2024, you'll join conversations on: 💢 Autoimmune applications of cell therapy, with advice from Cabaletta Bio & Adicet Bio, Inc 💢 How to innovate and accelerate your manufacturing processes with first-hand learnings from Gracell Biotechnologies, Kyverna Therapeutics, Takeda, Bristol Myers Squibb & Verismo Therapeutics 💢 How to improve efficacy in solid tumors with insights from Affini-T Therapeutics, Inceptor Bio, Obsidian Therapeutics & Memorial Sloan Kettering Cancer Center 💢 Advice and insights from investors including Vida Ventures, LLC, Sofinnova Partners & Northpond Ventures, plus how to secure cash runways with experienced players like Daiichi Sankyo US, Bristol Myers Squibb & Takeda Full details in the agenda here: https://ter.li/eugziv This is also your biggest networking opportunity of the year as 1,000+ cell therapy experts come together to collaborate, build professional networks and socialize with new and old friends. Don't be the only one to miss it! Best value tickets are available now. Access your saving here: https://ter.li/d87kfc Isabella Maxton Jade Wallace Elly Kanaan Kiran Thomson Luke O'Neill Molly Jones Molly Biggin Rebecca Legge Sadhbh Ni Chiobhain

𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐏𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐰𝐢𝐭𝐡 𝐃𝐫𝐞𝐧 𝐁𝐢𝐨 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 Novartis Novartis has entered a strategic collaboration with Dren Bio Dren Bio, Inc. to develop bispecific antibodies for cancer. This includes a $150 million upfront payment, $25 million equity investment, and up to $2.85 billion in potential milestones. Dren Bio’s platform targets myeloid cells to enhance therapeutic effects and safety. Novartis will handle clinical development, manufacturing, regulatory, and commercialization activities. This partnership adds to Novartis’ recent deals, including acquisitions of Mariana Oncology and a partnership with PeptiDream. #Novartis #Oncology #CancerTreatment #BispecificAntibodies #Biotech #Pharma #ImmunoOncology #ClinicalDevelopment #HealthcareInnovation #DrenBio #Partnerships

European biotechs Oxitope Pharma and Arxx Therapeutics have merged to form Calluna Pharma, a cutting-edge biotech company, and have successfully raised $81 million to advance its monoclonal antibody pipeline. Monoclonal antibodies hold immense promise in revolutionizing healthcare, providing targeted treatments for various diseases. Calluna's ambitious strides in this field underscore their commitment to innovation and the betterment of global health. It’s already been a big year for immunotherapies, as earlier this month, pharma giant Boehringer Ingelheim teamed up with 3T Biosciences in a deal totalling $538.5m to advance cancer immunotherapies. #biotech #innovationinhealthcare #monoclonalantibodies #immunotherapy

Our portfolio company HAYA Therapeutics has been recognized by Labiotech.eu as one of the top 18 biotech startups in Switzerland, spotlighting its innovative approach to targeting non-coding RNAs to combat fibrotic diseases and age-related conditions: https://lnkd.in/gnPbAhQ As reported by The Financial Times, a groundbreaking anti-aging therapy that mimics regenerative processes seen in axolotl salamanders has shown promise in extending the lifespan of mice by 25%. Read more about the treatment that targets the pro-inflammatory protein IL-11: https://lnkd.in/guvdqyFH New hires at our portfolio companies: HAYA Therapeutics welcomes Eric Adam as their new COO, bringing his extensive experience from the pharmaceutical and diagnostics industries to support their growth and scientific exploration. Meanwhile, Auron Therapeutics, Inc. introduces Serge Messerlian to their board, enhancing their leadership as they advance their innovative cancer therapeutics platform. #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital